Yang Han1, Dong Guo, Yao Chen, Yu Chen, Zhi-Rong Tan, Hong-Hao Zhou. 1. Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, 110 Xiangya Road, Changsha, Hunan 410078, P.R. China.
Abstract
PURPOSE: To investigate the effects of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 and its relationship with CYP2C9 genotypes. METHODS:Twelve healthy adult men of known CYP2C9 genotype (six CYP2C9*1/*1 and six CYP2C9*1/*3) were recruited in a two-phase randomized crossover design study. The pharmacokinetics of losartan and E-3174 were measured before and after a 14-day treatment with 140 mg of silymarin three times daily. RESULTS: The area under the plasma concentration-time curve (AUC) of losartan increased significantly following a 14-day silymarin treatment in subjects with the CYP2C9*1/*1 genotype, but not in those with the CYP2C9*1/*3 genotype. The AUC of E-3174 decreased significantly with a silymarin pretreatment in both CYP2C9*1/*1 and the CYP2C9*1/*3 subjects. The metabolic ratio of losartan (ratio of AUC(0-infinity) of E-3174 to AUC(0-infinity) of losartan) decreased significantly after a 14-day treatment with silymarin in individuals with the CYP2C9*1/*1 genotype (p < 0.05), but not in those with the CYP2C9*1/*3 genotype (p = 0.065). CONCLUSION:Silymarin inhibits the metabolism of losartan to E-3174, with the magnitude of the interaction differing in individuals with different CYP2C9 genotypes.
RCT Entities:
PURPOSE: To investigate the effects of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 and its relationship with CYP2C9 genotypes. METHODS: Twelve healthy adult men of known CYP2C9 genotype (six CYP2C9*1/*1 and six CYP2C9*1/*3) were recruited in a two-phase randomized crossover design study. The pharmacokinetics of losartan and E-3174 were measured before and after a 14-day treatment with 140 mg of silymarin three times daily. RESULTS: The area under the plasma concentration-time curve (AUC) of losartan increased significantly following a 14-day silymarin treatment in subjects with the CYP2C9*1/*1 genotype, but not in those with the CYP2C9*1/*3 genotype. The AUC of E-3174 decreased significantly with a silymarin pretreatment in both CYP2C9*1/*1 and the CYP2C9*1/*3 subjects. The metabolic ratio of losartan (ratio of AUC(0-infinity) of E-3174 to AUC(0-infinity) of losartan) decreased significantly after a 14-day treatment with silymarin in individuals with the CYP2C9*1/*1 genotype (p < 0.05), but not in those with the CYP2C9*1/*3 genotype (p = 0.065). CONCLUSION:Silymarin inhibits the metabolism of losartan to E-3174, with the magnitude of the interaction differing in individuals with different CYP2C9 genotypes.
Authors: J B McCrea; A Cribb; T Rushmore; B Osborne; L Gillen; M W Lo; S Waldman; T Bjornsson; S Spielberg; M R Goldberg Journal: Clin Pharmacol Ther Date: 1999-03 Impact factor: 6.875
Authors: A Sachinidis; Y Ko; P Weisser; M K Meyer zu Brickwedde; R Düsing; R Christian; A J Wieczorek; H Vetter Journal: J Hypertens Date: 1993-02 Impact factor: 4.844
Authors: Chitra Sridar; Theunis C Goosen; Ute M Kent; J Andrew Williams; Paul F Hollenberg Journal: Drug Metab Dispos Date: 2004-06 Impact factor: 3.922
Authors: Roman Zuber; Martin Modrianský; Zdenek Dvorák; Petr Rohovský; Jitka Ulrichová; Vilím Simánek; Pavel Anzenbacher Journal: Phytother Res Date: 2002-11 Impact factor: 6.388